Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
40 results
D1.151 - Changes in Treatment Steps After Biological Therapy in Patients with Severe Asthma: Real-World Data
D1.139 - Dupilumab was Effective in Black and Non-Black Patients with Asthma Completing 1 Year of the RAPID Registry
D1.140 - Beyond Severe Asthma: Eosinophilic Granulomatosis with Polyangiitis Unmasked by Acute Myopericarditis
D1.141 - Added value of impulse oscillometry in the early detection of small airway dysfunction in asthma
D1.142 - Clinical remission in long-term biological therapy of severe asthma
D1.143 - Clinical Efficacy of Biologics and ATAD in NSAID-Exacerbated Respiratory Disease: A Phenotype-Based Comparative Study
D1.144 - Eosinophilic myocarditis as a complication of dupilumab treatment
D1.145 - Clinical Impact of Type 2 Phenotype in Severe Asthma Patients with Exacerbations During Biologic Treatment
D1.146 - Improved nocturnal oxygenation in a severe allergic asthma patient with comorbid sleep apnea under anti-TSLP biologic therapy
D1.147 - Efficacy of benralizumab in Chinese patients with severe eosinophilic asthma: subgroup analysis of the 16-week results from STEP, a phase IIIb study of step-down maintenance therapy
D1.148 - Real-world effectiveness of dupilumab administered every 4 weeks in patients with moderate to severe asthma
D1.149 - Healthcare Professionals Typically Apply Higher Blood Eosinophil Count Thresholds for Biologic Selection Versus Clinical Guidelines in Severe Asthma
D1.150 - Patient characteristics and treatment patterns in adults with severe asthma in Poland (POLSAR): a retrospective, single-center real-world cohort from ISAR
D1.152 - Treatment-induced remission after mepolizumab discontinuation: case series
D1.153 - Indirect Comparison of Biological Agents in Severe Asthma: Real-World Data
D3.181 - Oral Immunotherapy for food allergy through a personalised approach
D3.182 - Initiating Sublingual Immunotherapy in Pre-Adolescence (
D3.193 - Dual Blockade of TSLP and IL11 with a bispecific antibody: A Promising Strategy for the Treatment of Asthma and Other Airway Disorders
D3.194 - Carry-Over Effect of House Dust Mite (HDM) Immunotherapy for Allergic Respiratory Conditions in Pediatric and Adolescent Populations: A Systematic Review and Narrative Synthesis
D3.189 - Oral Immunotherapy–Associated Eosinophilic Esophagitis: A Pediatric Case Report
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download